Biostimulators and Hybrid Injectable Therapies in Contemporary Aesthetic Medicine

Non-surgical facial rejuvenation has progressed significantly beyond the paradigm of simple volumetric replacement. Although hyaluronic acid (HA) fillers remain a cornerstone of aesthetic practice, increasing emphasis is now placed on biostimulatory and regenerative injectable therapies that aim to restore dermal architecture, improve tissue quality, and stimulate endogenous collagen production.¹²

This shift reflects evolving patient expectations toward more natural, progressive, and durable outcomes, as well as growing interest in concepts such as collagen preservation and “collagen banking.”³

In response, a diverse range of injectable products has emerged, spanning pure collagen stimulators, dual-action volumisers, and hybrid formulations.

Among these, poly-L-lactic acid (PLLA), calcium hydroxylapatite (CaHA), and poly-D,L-lactic acid (PDLLA)-based injectables, both alone and in combination with HA, have become widely adopted. This review examines four commonly used agents—Sculptra, Radiesse, Juvelook, and Lenisna—focusing on their composition, mechanism of action, duration of effect, delivery techniques, clinical indications, and complication profiles.

---

Sculptra: A Poly-L-Lactic Acid Biostimulator

Composition

Sculptra is composed of microparticles of poly-L-lactic acid (PLLA), a biocompatible and biodegradable synthetic polymer belonging to the alpha-hydroxy acid family. PLLA has been extensively used in absorbable medical devices and sutures, supporting its established safety profile.⁴⁵

Mechanism of Action

Sculptra acts as a delayed-onset injectable implant. Following injection, PLLA microparticles elicit a controlled subclinical inflammatory response, leading to fibroblast activation and subsequent neocollagenesis.

Newly synthesised collagen progressively replaces the resorbing polymer, resulting in gradual volume restoration and dermal thickening.⁶³

Duration of Action

Clinical improvement develops over several months, with outcomes typically persisting for up to 24 months or longer, depending on treatment protocol and individual patient response.⁴

Method of Delivery

Sculptra is most commonly administered using a cannula and deposited in the deep dermal or subcutaneous plane. Treatment protocols usually involve multiple sessions spaced 4–6 weeks apart, following appropriate reconstitution.³

Areas of Use

• Generalised facial volume loss
• Mid and lower-face structural support
• Correction of deep folds and contour deficiencies

Complications

Transient adverse effects include oedema, ecchymosis, erythema, and tenderness. Delayed subcutaneous nodules or granulomas have been reported, particularly with superficial placement or inadequate dilution.

As PLLA is non-reversible, vascular occlusion—though rare—represents a significant complication requiring urgent management.⁷

---

Radiesse: Calcium Hydroxylapatite Structural Biostimulation

Composition

Radiesse consists of calcium hydroxylapatite (CaHA) microspheres (approximately 30%) suspended in a carboxymethylcellulose gel carrier. CaHA is a naturally occurring mineral component of bone and teeth, conferring excellent biocompatibility.⁸

Mechanism of Action

The gel carrier provides immediate volumisation, while CaHA microspheres act as a scaffold that promotes fibroblast-mediated production of collagen and elastin as the carrier resorbs.⁹

Duration of Action

Clinical effects generally persist for 12–18 months, with variability related to anatomical location and injection technique.⁸¹⁰

Method of Delivery

Radiesse is delivered via needle or cannula into subcutaneous or periosteal planes. Lidocaine-containing formulations are frequently used to enhance patient comfort.⁹

Areas of Use

• Midface volumisation
• Jawline and chin contouring
• Nasolabial folds
• Neck rejuvenation
• Dorsal hand rejuvenation

It is not recommended for the lips or periocular region.¹⁰

Complications

Common reactions include bruising, swelling, and tenderness. Palpable nodules may occur with superficial placement. As CaHA is non-dissolvable, vascular compromise constitutes a serious adverse event requiring prompt intervention.⁷

---

Juvelook: Hybrid PDLLA and Hyaluronic Acid Injectable

Composition

Juvelook is a hybrid injectable comprising poly-D,L-lactic acid (PDLLA) microparticles combined with non-cross-linked hyaluronic acid (HA). PDLLA serves as the biostimulatory component, while HA provides immediate hydration and subtle volumisation.¹¹

Mechanism of Action

Juvelook exhibits a dual mechanism: immediate improvement in hydration and skin luminosity from HA, followed by progressive collagen and elastin synthesis stimulated by PDLLA microparticles. The randomised D- and L-lactic acid polymer structure maximises tissue surface contact. In addition, PDLLA has been shown to modulate the NF-κB inflammatory pathway, reducing collagen degradation and oxidative stress.²

Duration of Action

Immediate effects are observed post-treatment, with progressive improvement over weeks. Clinical benefits typically persist for 12–18 months, with ongoing collagen stimulation beyond visible effects.¹¹

Method of Delivery

Juvelook is injected into the dermis or mid-dermis using a fine needle or cannula. Owing to its small particle size, it may also be administered via microneedling.²

Areas of Use

• Tear troughs and periocular rejuvenation
• Perioral fine lines
• Neck and décolletage
• Acne scarring and textural irregularities

It also improves pigmentation, pore size, elasticity, and overall skin quality.¹¹

Complications

Transient swelling and bruising are most commonly reported. Due to the small particle size (20–40 μm), vascular occlusion has not been reported. Superficial placement may result in palpable irregularities. Juvelook is thermally modifiable, allowing softening with heat and saline if required.¹²

Before Treatment

After Treatment

---

Lenisna: High-Concentration PDLLA Structural Biostimulator

Composition

Lenisna shares the same manufacturer as Juvelook and combines PDLLA microparticles with non-cross-linked HA, but at a substantially higher PDLLA concentration (170 mg versus 42.5 mg). This formulation is designed to address deeper structural volume loss.¹²

Mechanism of Action

Lenisna provides immediate hydration from HA, followed by progressive collagen induction and tissue reinforcement as PDLLA stimulates fibroblasts within deeper tissue planes.²

Duration of Action

Clinical effects typically persist for 18–24 months. Initial protocols often involve 2–3 sessions spaced approximately 8 weeks apart, with maintenance treatment at 18–24 months.¹²

Method of Delivery

Lenisna is delivered using a 25G cannula into the subcutaneous plane to achieve optimal structural support.

Areas of Use

• Facial contouring (forehead, temples, cheeks, chin)
• Deep wrinkles (nasolabial folds, marionette lines)
• Deep scars

Lenisna is not indicated for periocular use.

Complications

Adverse effects are generally mild and transient, including bruising and swelling. Nodularity may occur with superficial placement. Similar to Juvelook, Lenisna is heat-reversible, allowing corrective softening when required.¹²

---

Conclusion

Sculptra, Radiesse, Juvelook, and Lenisna represent distinct yet complementary tools within regenerative aesthetic medicine. Understanding their compositional differences, mechanisms of action, and safety profiles allows clinicians to tailor treatments according to anatomical requirements, ageing patterns, and patient expectations.

As biostimulatory injectables continue to evolve, careful patient selection, anatomical expertise, and adherence to evidence-based protocols remain essential to achieving safe, natural, and durable outcomes.

---

Conflict of Interest Statement

The author declares a professional relationship relevant to the content of this manuscript. The author works as a clinical trainer for FILLMED, a company that has entered into a strategic partnership with VAIM Global, the manufacturer of Lenisna®, Juvelook®, and NCTF®. This role includes educational and training activities related to aesthetic injectable products. The content of this article has been prepared to provide an objective, evidence-based review of biostimulatory injectable treatments. No financial incentives, sponsorship, or editorial influence from the aforementioned companies were received specifically for the preparation of this manuscript.

---

 CaHA = calcium hydroxylapatite

References (Vancouver Style)

1. Lorenc ZP, et al. Biostimulatory fillers: clinical considerations and safety. Aesthet Surg J. 2018;38 Suppl 1:S17-S24. doi:10.1093/asj/sjy012.
2. Kim JE, et al. Biostimulatory fillers: mechanism of action, clinical applications, and safety. Plast Reconstr Surg. 2021;147(2):343-351. doi:10.1097/PRS.0000000000007540.
3. Matarasso SL, et al. Consensus recommendations for the use of injectable poly-L-lactic acid in aesthetic medicine. Aesthet Surg J. 2015;35(3):294-306. doi:10.1093/asj/sju102.
4. Brandt FS, Cazzaniga A. Poly-L-lactic acid fillers: a review of safety and efficacy. Dermatol Surg. 2008;34 Suppl 1:S23-S30. doi:10.1111/j.1524-4725.2008.34250.x.
5. Callan P, Goodman GJ, Carlisle I. Poly-L-lactic acid: a review of clinical safety and efficacy. J Drugs Dermatol. 2013;12(1):74-80.
6. Goldberg DJ, et al. Long-term safety and efficacy of poly-L-lactic acid for facial lipoatrophy. J Cosmet Laser Ther. 2013;15(4):202-207. doi:10.3109/14764172.2013.793826.
7. De Boulle K, et al. Management of complications after injection of dermal fillers. J Cosmet Dermatol. 2013;12(4):279-287. doi:10.1111/jocd.12054.
8. Beer K. A single-center, randomized controlled study of calcium hydroxylapatite for the correction of nasolabial folds. Dermatol Surg. 2009;35 Suppl 2:1206-1213. doi:10.1111/j.1524-4725.2009.01217.x.
9. Christensen LH, et al. Consensus recommendations for the use of calcium hydroxylapatite fillers in facial aesthetics. J Cosmet Dermatol. 2016;15(4):373-382. doi:10.1111/jocd.12234.
10. Biesman BS, et al. Calcium hydroxylapatite for rejuvenation of the dorsal hands: results from a randomized, multicenter trial. Aesthet Surg J. 2015;35(3):341-352. doi:10.1093/asj/sju093.
11. Lee WJ, et al. Poly-D,L-lactic acid fillers for facial rejuvenation: histologic evaluation and clinical outcomes. Dermatol Surg. 2020;46(9):1159-1166. doi:10.1097/DSS.0000000000002396.
12. VAIM Global. Juvelook® and Lenisna®: product information and clinical guide [Internet]. 2024 [cited 2026 Jan 15]. Available from: https://www.juvelook.com